Chamaiporn Chalongkhwan. Development of recombinant probiotic for disease control in nile tilapia (Oreochromis Niloticus, LINN.). Master's Degree(Genetic Engineering). Kasetsart University. Office of the University Library. : Kasetsart University, 2017.
Development of recombinant probiotic for disease control in nile tilapia (Oreochromis Niloticus, LINN.)
Abstract:
Streptococcus agalactiae is one of seriously infectious bacteria of the streptococcosis disease which causes the devastation in tilapia cultures. Nowadays, an important method for control of this disease is the vaccination. This method has some drawback such as easily to introduce stress to animals, requires skilled labor, and the application is time consuming. Therefore, the development of an oral DNA vaccine is interesting with supposing that this method would enhance vaccine efficacy and easily to manipulation. In this study, the development of probiotic-Bacillus subtilis as an orally DNA vaccine delivery system harboring S. agalactiae immunogenic gene was performed. The immunoreactive proteins of S. agalactiae serotype Ia and III were identified by immunoproteomics analysis. There are 44 immunoreactive proteins identified from serotype Ia and 64 immunoreactive proteins from serotype III were isolated. Among them, it is revealed that 10 immunoreactive proteins were found in both serotype. Then, five candidate immunoreactive genes including Pyk, GAPDH, SAG1407, Sip and SPB1 were cloned into pBEsDNA expression vector carrying secretory signal peptide of B. subtilis. The recombinant plasmids were successfully constructed and designated as pBEsDNA-Pyk_SP, pBEsDNA-GAPDH_SP, pBEsDNA-SAG1407_SP, pBEsDNA-Sip_SP and pBEsDNA-SPB1_SP. The recombinant expression plasmids were completely transformed into B. subtilis and successfully developed recombinant B. subtilis to use as a delivery vehicle of oral DNA vaccines. Whereas, protein expression in recombinant Bacillus was found false positive results makes it needed more investigation. Hence, protein expression in recombinant Bacillus might be improving along with tilapia challenge test which will be performed to determine the orally-vaccine efficacy in further investigation.
Kasetsart University. Office of the University Library